Log In Or Register For Full Access
Close
Username
Password
 Forgot username or password?
Not Registered?
Leaving This Site
Close
You are now leaving GSKSource.
Please note that links to non-GSK sites are provided as a courtesy to GSKSource users, but that GSK is not responsible for the content found therein.
                                    
GSK Employee Access
Close
GlaxoSmithKline employees must use their GSK laptop/desktop and must be logged into the GSK network to access this site.
If you are logged into the GSK network, please select continue to access the site.
                                    
Important Notice
This site is intended for US Healthcare Professionals. By clicking continue, you are acknowledging that you are a US Healthcare Professional.
FLUARIX® QUADRIVALENT
(Influenza Virus Vaccine)
Product Overview

Helps deliver broader coverage with 4 strains of influenza.
Learn More

Indication

FLUARIX QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUARIX QUADRIVALENT is approved for use in persons 3 years of age and older.

Important Safety Information

  • Do not administer FLUARIX QUADRIVALENT to anyone with known severe allergic reactions (anaphylaxis) to any component of the vaccine, including egg protein, or a life-threatening reaction to previous administration of any influenza vaccine.
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give FLUARIX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
  • The tip caps of the prefilled syringes may contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals.
  • If FLUARIX QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons.
  • Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.
  • In clinical trials with FLUARIX QUADRIVALENT, the most common adverse reactions in adults were pain at the injection site, muscle aches, headaches, and fatigue. In children 3 through 17 years of age, injection site adverse reactions were pain, redness, and swelling. In children 3 through 5 years of age, the most common systemic adverse events were drowsiness, irritability, and loss of appetite. In children 6 through 17 years of age, the most common systemic adverse events were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLUARIX QUADRIVALENT for other potential adverse reactions and events.)
  • Vaccination with FLUARIX QUADRIVALENT may not result in protection in all vaccine recipients.

About FLUARIX QUADRIVALENT

Helps deliver broader coverage with 4 strains of influenza [1]

Expanding coverage to two influenza A strains
and two influenza B strains

Expanding coverage to two influenza A strains
and two influenza B strains

  • FLUARIX QUADRIVALENT covers 4 strains of influenza virus (two influenza A and two influenza B), for broader coverage vs current trivalent inactivated influenza vaccines (IIV3) (two influenza A and one influenza B) [1]
  • A safety profile comparable to trivalent inactivated influenza vaccines [1]
  • Indicated for use in persons 3 years of age and older
  • CPT® code is 90686
  • Available in single-dose, prefilled, and prelabeled TIP-LOK® syringes
    • The tip caps of the prefilled syringe of FLUARIX QUADRIVALENT may contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals. The rubber plunger does not contain latex.
CPT is a registered trademark of the American Medical Association.
FLUARIX and TIP-LOK are registered trademarks of GlaxoSmithKline.
Manufactured by GlaxoSmithKline Bilogicals, Dresden, Germany, a branch of SmithKline Beecham.
Pharma GmbH & Co. KG, Munich Germany
Licensed by GlaxoSmithKline Biologicals, Rixensart, Belgium, US License 1617
Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709
  • FLUARIX QUADRIVALENT covers 4 strains of influenza virus (two influenza A and two influenza B), for broader coverage vs current trivalent inactivated influenza vaccines (IIV3) (two influenza A and one influenza B) [1]
  • A safety profile comparable to trivalent inactivated influenza vaccines [1]
  • Indicated for use in persons 3 years of age and older
  • CPT® code is 90686
  • Available in single-dose, prefilled, and prelabeled TIP-LOK® syringes
  • The tip caps of the prefilled syringe of FLUARIX QUADRIVALENT may contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals. The rubber plunger does not contain latex.
CPT is a registered trademark of the American Medical Association.
FLUARIX and TIP-LOK are registered trademarks of GlaxoSmithKline.
Manufactured by GlaxoSmithKline Bilogicals, Dresden, Germany, a branch of SmithKline Beecham.
Pharma GmbH & Co. KG, Munich Germany
Licensed by GlaxoSmithKline Biologicals, Rixensart, Belgium, US License 1617
Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709

Required Information

A state licence number is required to be on file for the state in which samples will be delivered
State Licence Number Licensing State